Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Elevated absolute monocyte counts (AMCs) have been reported to indicate poor prognosis for patients with lymphoproliferative disease, including those with follicular lymphoma (FL) receiving various treatments. We evaluated the prognostic impact of AMC in 150 consecutive FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Progression-free survival (PFS) did not differ significantly according to the AMC level. Univariate and multivariate analyses did not indicate a prognostic significance of AMC for PFS. Thus, the AMC is not a prognostic factor for FL patients treated with R-CHOP. However, immunochemotherapy might influence the prognostic impact of AMC.
Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Reina
R
Watanabe
Naoto
N
Tomita
Kumiko
K
Kishimoto
Satoshi
S
Koyama
Eriko
E
Ogusa
Yoshimi
Y
Ishii
Kazuho
K
Miyashita
Shiro
S
Matsuura
Shin
S
Fujisawa
Yukako
Y
Hattori
Hirotaka
H
Takasaki
Atsuko
A
Fujita
Rika
R
Ohshima
Hideyuki
H
Kuwabara
Chizuko
C
Hashimoto
Katsumichi
K
Fujimaki
Rika
R
Sakai
Yoshiaki
Y
Ishigatsubo
D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008224:Lymphoma, Follicular / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009000:Monocytes; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Follicular lymphoma; Monocyte; Prognosis